Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma).
Dummer R, Keilholz U, ESMO Guidelines Committee
Ann Oncol. 2016 Sep;27(suppl 5):v136-v137.
PMID: 27664250 [PubMed - as supplied by publisher]

appendix 1: Cutaneous melanoma (1): eUpdate published online September 2016 (www.esmo.org/Guidelines/Melanoma).
ESMO Guidelines Committee
Ann Oncol. 2016 Sep;27(suppl 5):v134-v135.
PMID: 27664249 [PubMed - as supplied by publisher]

Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: An umbrella review of meta-analyses.
Belbasis L, Stefanaki I, Stratigos AJ, Evangelou E
J Dermatol Sci. 2016 Sep 13;():.
PMID: 27663092 [PubMed - as supplied by publisher]

Prognostic Implication of Lymphovascular Invasion Detected by Double Immunostaining for D-40 and MITF1 in Primary Cutaneous Melanoma: Beware of MITF1 Specificity and Sensitivity in Unusual Melanoma Subtypes.
Creytens D
Am J Dermatopathol. 2016 Sep 19;():.
PMID: 27655125 [PubMed - as supplied by publisher]

Lymphangioinvasion in routine H & E staining is strongly associated with poor clinical outcome in lymph-node negative cutaneous melanoma patients.
Donizy P, Kaczorowski M, Halon A, Leskiewicz M, Matkowski R
Folia Histochem Cytobiol. 2016 Sep 21;():.
PMID: 27654015 [PubMed - as supplied by publisher]


NCBI's Disclaimer and Copyright notice